Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NHPLRYlCeG:ydH;zbZMhSXO|YYm= MnTjNgKBmzYEoN88US=> NYrXR3E6PDhiaB?= M4DDXolvcGmkaYTzJINmdGxiZ4Lve5Rp MWKyOlMzQTZyOB?=
PLC/PRF/5  NFfuNmdCeG:ydH;zbZMhSXO|YYm= MYWx5qCUPcLizszN MWK0PEBp M{DHbolvcGmkaYTzJINmdGxiZ4Lve5Rp NG\kZXozPjN{OU[wPC=>
HepG2  NH[4fZpCeG:ydH;zbZMhSXO|YYm= M1P3U|HjiJN3wrFOwG0> M1n1R|Q5KGh? NXG3SYE2cW6qaXLpeJMh[2WubDDndo94fGh? M{DTRlI3OzJ7NkC4
HEK293 NH\yO4NHfW6ldHnvckBCe3OjeR?= MYGwMlXjiIoQvF2= NUHlOG5xOi92L{[gbC=> M4H4XpJm\HWlZYOgS3JRPzhiZYjwdoV{e2mxbh?= MVqyOVg2QDB|Mh?=
GEO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMlAyNTJyIN88US=> M{nNVFk3KGh? NHLpfFNFVVOR M1ntZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEfVe2IzPTh|OEO5NS=>
SW48 NEnEXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP5RpExNjBzLUKwJO69VQ>? NHTkN2U6PiCq M2\PdmROW09? MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGTkb4MzPTh|OEO5NS=>
HT29 NGSxbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfDPJJUOC5yMT2yNEDPxE1? M{nMPFk3KGh? NEPv[GZFVVOR MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVOyOVg{QDN7MR?=
SW480 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHzTFUxNjBzLUKwJO69VQ>? MnvFPVYhcA>? NGDrbXBFVVOR MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYPLcXY1OjV6M{izPVE>
SW620 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fu[FAvODFvMkCg{txO NXTESlFvQTZiaB?= NX\OS5FsTE2VTx?= MoPQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4D0WFI2QDN6M{mx
HCT116 M3XaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDiNE4xOS1{MDFOwG0> MUK5OkBp M2rsc2ROW09? MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGnoblkzPTh|OEO5NS=>
LOVO NVfiPXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlAyNTJyIN88US=> MU[5OkBp NVvWTm1MTE2VTx?= NGfhUmxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2PWUVI2QDN6M{mx
HCT150 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjPNE4xOS1{MDFOwG0> NIX2Um46PiCq NIOwWlhFVVOR NWDrUZMzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVuyOVg{QDN7MR?=
SW48-CR MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMlAyNTJyIN88US=> M1rGWFk3KGh? M2TBfGROW09? MlfobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUDXO3JyOjV6M{izPVE>
GEO-CR M4LPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMlAyNTJyIN88US=> NUfOeZN4QTZiaB?= MXfEUXNQ NWDOfHI2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MU[yOVg{QDN7MR?=
KB-31 NYraUItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnkZ4pIUUN3ME21MlXDuTBwMzDuUS=> NWXXbYZ2OjV5NUOzOlE>
KB-G2 M2HJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrETWM2OD17LkJCtVAvOSCwTR?= M4KwSlI2PzV|M{[x
LLC-PK1 M1XBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR{LkFCtVMvOiCwTR?= MonuNlU4PTN|NkG=
LLC-PK1/MRP2 NVfYRo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXFemdiUUN3ME24Nk41yrF{Lkegcm0> NHHnOWczPTd3M{O2NS=>
HEK293 M1HWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz0TWM2OD1zMT6wxtEyNjJibl2= M13OUFI2PzV|M{[x
HEK293/OATP1B1 NUjyb4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7sTWM2OD14LkNCtVAvOyCwTR?= NILhd4wzPTd3M{O2NS=>
HROC18 M1PoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMzFOwG0> MWqyOVMxQTlzNB?=
HROC24 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XuRmlEPTB;ND62JO69VQ>? MWSyOVMxQTlzNB?=
HROC43 M3jwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjNNndKSzVyPUWuN{DPxE1? M1;E[|I2OzB7OUG0
HROC46 M3fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwNDFOwG0> NYmwR3hoOjV|MEm5NVQ>
RJ345 MV7GeY5kfGmxbjDBd5NigQ>? MWmwMlUwPSEQvF2= NWTLeZBqOjRiaB?= Mmn4SG1UVw>? M{\wcolvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> NUXXO2xkOjV{NUO5PVQ>
RJ348 NYjBOpNkTnWwY4Tpc44hSXO|YYm= MYKwMlUwPSEQvF2= M3\6WVI1KGh? NIXnUIxFVVOR MX\pcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= NXnaOWlWOjV{NUO5PVQ>
MCF-7 NIPSfoxHfW6ldHnvckBCe3OjeR?= M2XyfFAvPS93IN88US=> MoLRNlQhcA>? MlezSG1UVw>? M{TXbolvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> NW\hWVRrOjV{NUO5PVQ>
MDA-MB-231 NIm5b|hHfW6ldHnvckBCe3OjeR?= NWPoW|k1OC53L{Wg{txO MWmyOEBp NIS5cXRFVVOR NHTn[oFqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> M321ZlI2OjV|OUm0
HT15 NFnsbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P0SlEuOjBizszN MkfnOFghcA>? NW[4SJlGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEe1OVIzPTB5MUCxPC=>
DLD1 NXTyfoJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2iwOlEuOjBizszN NFrUSnI1QCCq Ml[4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NY\0XFd3OjVyN{GwNVg>
HT-29 M3jZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGntUlUyNTJyIN88US=> NX6wZ5pnPDhiaB?= M37uRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml\PNlUxPzFyMUi=
Hct-116 M{Dmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33QOFEuOjBizszN MoLxOFghcA>? Mn3pbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGW2cmMzPTB5MUCxPC=>
HT15 M3XQc2Fxd3C2b4Ppd{BCe3OjeR?= MVWxMVExKM7:TR?= NF\iZZM1QCCq NFjqS5dqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUCyOVA4OTBzOB?=
DLD1 Ml62RZBweHSxc3nzJGF{e2G7 MY[xMVExKM7:TR?= MlPqOFghcA>? MVzpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MknGNlUxPzFyMUi=
HT-29 NYXkfJVzSXCxcITvd4l{KEG|c3H5 MlfENU0yOCEQvF2= M4WzW|Q5KGh? NFmxXnNqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH3p[3YzPTB5MUCxPC=>
Hct-116 MkXCRZBweHSxc3nzJGF{e2G7 MYmxMVExKM7:TR?= MnfvOFghcA>? MX7pcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlrpNlUxPzFyMUi=
GBM5 NEDiNGFCeG:ydH;zbZMhSXO|YYm= MkjtNE426oDVMT6w5qCK|ryP NHm0[2kzPCCq MUHEUXNQ MmPtbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MlP6NlQ6OTF{MUW=
GBM6 M3;5T2Fxd3C2b4Ppd{BCe3OjeR?= NEHLR24xNjYkgKOxMlDjiIoQvF2= NXjKUGNYOjRiaB?= NFzBW5pFVVOR MoDSbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo M{TyTFI1QTFzMkG1
GBM12 MWjBdI9xfG:|aYOgRZN{[Xl? NHrSNZoxNjYkgKOxMlDjiIoQvF2= MXGyOEBp NWHMeFZYTE2VTx?= MkDzbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo NUmwRnl7OjR7MUGyNVU>
GBM14  M4TDSWFxd3C2b4Ppd{BCe3OjeR?= M{DFXFAvPeLCk{GuNQKBkc7:TR?= M2n3fFI1KGh? MX;EUXNQ NUO4NnpzcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NWnMXJFVOjR7MUGyNVU>
Hep3B MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOx5qCUOi53wrFOwG0> MVuyOE81QC95MjDo MYPpcohq[mm2czDj[YxtKGe{b4f0bC=> M1fyeFI1QDh3OEmw
PLC/PRF/5  NXjn[XA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuNgKBmzJwNdMg{txO NH;teIYzPC92OD:3NkBp MmjYbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M331UFI1QDh3OEmw
HepG2  NFS0UIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK4UotJOeLCk{KuOeKh|ryP NV3JdZRuOjRxNEivO|IhcA>? MkfHbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3q2O|I1QDh3OEmw
HCT116  M372ZWZ2dmO2aX;uJGF{e2G7 MnXuNVAwOjBxNECg{txO MX[yOEBp NE\weIxqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:wIHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MU[yOFc3OzZzMR?=
Lim2405 MXrGeY5kfGmxbjDBd5NigQ>? NVT4O3JWPDBizszN M3PIfFI1KGh? MWjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MXqyOFc3OzZzMR?=
LoVo NGLNSGVHfW6ldHnvckBCe3OjeR?= NF3T[mI1OCEQvF2= MYOyOEBp NIP0e3BqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? Mlq0NlQ4PjN4MUG=
Lim1215 MVfGeY5kfGmxbjDBd5NigQ>? NXW4OXB2PDBizszN MUGyOEBp MnX0bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ Mlm0NlQ4PjN4MUG=
SW48 NV7RS2h1TnWwY4Tpc44hSXO|YYm= NV7MTmh6PDBizszN Mne4NlQhcA>? MkHkbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MXqyOFc3OzZzMR?=
RKO  MoTFSpVv[3Srb36gRZN{[Xl? NG\wXHo1OCEQvF2= NHj4VWkzPCCq NGrM[oFqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NWO0fo1XOjR5NkO2NVE>
SW837 Ml3ESpVv[3Srb36gRZN{[Xl? MY[0NEDPxE1? MkD4NlQhcA>? M1fPR4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NUTyfXhFOjR5NkO2NVE>
SW1463 MUPGeY5kfGmxbjDBd5NigQ>? MXO0NEDPxE1? MnzjNlQhcA>? NIrVTXlqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? Ml7hNlQ4PjN4MUG=
SW480 MVLGeY5kfGmxbjDBd5NigQ>? Mn7IOFAh|ryP NFXmVIMzPCCq MWXpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NYDtTIs5OjR5NkO2NVE>
Vaco432 M{DERWZ2dmO2aX;uJGF{e2G7 NVjVZ3g3PDBizszN NV[0eHdKOjRiaB?= M2\nVIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M2XqXlI1PzZ|NkGx
Vaco400 NUDQ[YRDTnWwY4Tpc44hSXO|YYm= M37pdlQxKM7:TR?= M2DD[lI1KGh? NGHoelFqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M370ZlI1PzZ|NkGx
DLD1 MYDGeY5kfGmxbjDBd5NigQ>? MVm0NEDPxE1? NUfQNnZROjRiaB?= MYDpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NHvuOZAzPDd4M{[xNS=>
HT29  NX7ROWVHTnWwY4Tpc44hSXO|YYm= M3LScFQxKM7:TR?= MWmyOEBp NEfyZVBqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M{XBbVI1PzZ|NkGx
PLC/PRF/5  NGLCXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyx5qCUPcL3TR?= MnvsNlQwPDhxN{KgbC=> M{POVolvcGmkaYTzJINmdGxiZ4Lve5Rp MonWNlMyPjlzNEi=
HepG2 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDQNgKBmzYEtV2= M2fMWlI1NzR6L{eyJIg> MUnpcohq[mm2czDj[YxtKGe{b4f0bC=> MV2yN|E3QTF2OB?=
Hep3B  M2nVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMbFHjiJN3wsXN NFvrVHQzPC92OD:3NkBp M3\vWYlvcGmkaYTzJINmdGxiZ4Lve5Rp Mn3KNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID